14 batches of drugs are not qualified 7 batches of hot lamb.

September 25, Shandong Provincial Drug Administration Drug Quality Testing Notice (No. 6 of 2020).
notice shows that a total of 11 production enterprises of 5 varieties of a total of 14 batches of drugs sampling failed, the relevant drug regulatory departments for non-compliant products have taken seizure, seizure, suspension of sales, product recall and other control measures, and in accordance with relevant laws and regulations on the relevant production enterprises (preparation units), sampled units in accordance with the law serious investigation and punishment.
unqualified varieties are Chinese medicine drink tablets: Shan Tzu mushrooms, Wu Zhuyu, masturbation sheep (4 batches), Sichuan Wu, hot sheep (7 batches).
non-conforming testing items: characteristics, identification - micro-identification, content determination - total amount of obscenity and phosphate glycoside, content determination - masturbation, content determination.
In order to strengthen the supervision of drug quality and ensure the safety of public drug use, according to the annual sampling work plan of the provincial drug regulatory bureau, the provincial bureau has carried out spot checks and inspections on the quality of drugs produced, operated and used by the units, and now the spot checks found that the non-compliant drugs are notified as follows: First, after verification and confirmation, marking 11 production enterprises (preparation units) a total of 14 batches of drugs, after sampling does not meet the standards.
2. The relevant drug regulatory departments have taken control measures such as seizure, seizure, suspension of sales and product recall of non-compliant products, and shall, in accordance with relevant laws and regulations, seriously investigate and punish the relevant production enterprises (preparation units) and sampled units in accordance with the law, and may inquire about the website of the relevant municipal market supervision authority.
, for non-compliant products and corresponding production and operation enterprises and units, the relevant drug regulatory departments should strengthen supervision, urge them to identify the causes of the problems, formulate and implement corrective measures, and effectively eliminate hidden risks.
he hedding this notice.
, Shandong Province, China, September 24, 2020 (Public Attributes: Active Disclosure)